Haemonetics
256 hedge funds and large institutions have $6.15B invested in Haemonetics in 2019 Q2 according to their latest regulatory filings, with 49 funds opening new positions, 71 increasing their positions, 103 reducing their positions, and 49 closing their positions.
37% more capital invested
Capital invested by funds: $4.49B → $6.15B (+$1.66B)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 49
0.89% less ownership
Funds ownership: 100.56% → 99.67% (-0.89%)
2% less funds holding
Funds holding: 260 → 256 (-4)
31% less repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 103
50% less call options, than puts
Call options by funds: $1.07M | Put options by funds: $2.13M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
+$112M |
| 2 |
EC
Eminence Capital
New York
|
+$75.6M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$74.4M |
| 4 |
Neuberger Berman Group
New York
|
+$54.5M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
+$41.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HM
HealthCor Management
New York
|
-$99.1M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$51.1M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
-$40.5M |
| 4 |
BlackRock
New York
|
-$38M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$30.3M |
HAE Hedge Fund Activity: Q2 2019 in Review
256 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Haemonetics (HAE) for Q2 2019, worth a combined $6.15B — up 37% from $4.49B a quarter earlier.
Fund positioning in HAE was balanced in Q2 2019: 49 funds opened new positions, 49 closed out, 71 added to existing stakes and 103 trimmed.
The largest buyer was Capital Research Global Investors, adding an estimated $112M. The largest seller was HealthCor Management, cutting an estimated $99.1M.
- 256 institutional investors held Haemonetics (HAE) as of Q2 2019, down from 260 in Q1 2019.
- Funds reported $6.15B of Haemonetics stock for Q2 2019, up 37% quarter-over-quarter.
- 49 funds opened new Haemonetics positions in Q2 2019 and 49 closed out, a net change of 0 holders.
- The largest Haemonetics buyer in Q2 2019 was Capital Research Global Investors, an estimated $112M added.
- The largest Haemonetics seller in Q2 2019 was HealthCor Management, an estimated $99.1M sold.
Based on aggregated 13F filings for Q2 2019.